Abstract:OBJECTIVE:DC-CIK therapy included DC-CIK cells and Ag-DC-CIK cells. To further confirm whether DC-CIK reconstructs the antitumor immunity and improves the tumor responses and reveals its optimal usage and combination with chemotherapy, we systematically reevaluated all the related studies. MATERIALS AND METHODS:All studies about DC-CIK plus chemotherapy for NSCLC were collected from the published and ongoing database as CBM, CNKI, VIP, Wanfang, ISI, Embase, MEDLINE, CENTRAL, WHO-ICTRP, Chi-CTR, and US clinical trials (established on June 2017). We evaluated their methodological bias risk according to the Cochrane evaluation handbook of RCTs (5.1.0), extracted data following the predesigned data extraction form, and synthesized the data using meta-analysis. RESULTS:We included 28 RCTs (phase IV) with 2242 patients, but most trials had unclear bias risk. The SMD and 95% CI of meta-analysis for CD3+ T cells, CD3+ CD4+ T cells, CD3+ CD8+ T cells, CD4+/CD8+ T cell ratio, CIK cells, NK cells, and Treg cells were as follows: 1.85 (1.39 to 2.31), 0.87 (0.65 to 1.10), 1.04 (0.58 to 1.50), 0.75 (0.27 to 1.22), 3.87 (2.48 to 5.25), 1.51 (0.99 to 2.03), and -2.31(-3.84 to -0.79). The RR and 95% CI of meta-analysis for ORR and DCR were as follows: 1.38 (1.24 to 1.54) and 1.27 (1.20 to 1.34). All differences were statistically significant between DC-CIK plus chemotherapy and chemotherapy alone. Subgroup analysis showed that only DC-CIK cells could increase the CD3+T cells, CD3+ CD4+T cells, CD3+ CD8+T cells, and CD4+/CD8+ T cell ratio. In treatment with one cycle or two cycles and combination with NP or GP, DC-CIK could increase the CD4+/CD8+ T cell ratio. All results had good stability. CONCLUSIONS:DC-CIK therapy can simultaneously improve the antitumor immunity and tumor responses. DC-CIK therapy, especially DC-CIK cells, can improve antitumor immunity through increasing the T lymphocyte subsets, CIK cell, and NK cells in peripheral blood. The one cycle to two cycles may be optimal cycle, and the NP or GP may be optimal combination.

The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors

Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.

Cytokine-Induced Killer (cik) Cell Therapy for Patients with Hepatocellular Carcinoma: Efficacy and Safety

Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer

The Clinical Research of Cytokine-induced Killer Cells Co-culturing with Autologous Dendritic Cells on the Clinical Immunotherapy for

Effect of DC-CIK Combined with Chemotherapy on Advanced Non-small Cell Lung Cancer and Its Influence on Immune Function

Clinical Effect and Safety of Dendritic Cell-Cytokine-induced Killer Cell Immunotherapy for Pancreatic Cancer: a Systematic Review and Meta-Analysis.

2003-2013, a Valuable Study: Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Stage IV Breast Cancer.

Clinical Effects of Autologous Dendritic Cells Combined with Cytokine-Induced Killer Cells Followed by Chemotherapy in Treating Patients with Advanced Colorectal Cancer: a Prospective Study

Abstract 4394: Combination Therapy of Dendritic Cells and Cytokine-Induced Killer Cells Prolong Survival after the Removal of Tumor in Gastrointestinal Cancer

Effects of DC-CIK Cells Therapy on Immune Function of Patients with Hematological Malignancies

Clinical efficacy of autologous DC-CIK cells therapy for patients with advanced solid tumors

Immunotherapy of Patient with Hepatocellular Carcinoma Using Cytotoxic T Lymphocytes Ex Vivo Activated with Tumor Antigen-Pulsed Dendritic Cells

The Effects of Cytokine-Induced Killer Cells for the Treatment of Patients with Solid Tumors: a Clinical Retrospective Study

The study of clinical application of DC-CIK combined with chemotherapy on colon cancer

The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials.

The Efficacy and Safety of Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cell Therapy in Combination with TACE-Predominant Minimally-Invasive Treatment for

Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis.

Analysis of the Clinical Efficacy of Dendritic Cell –cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer

Cytokine-induced Killer Cells Promote Antitumor Immunity

Clinical efficiency of dendritic cells and cytokine-induced killer cells on local advanced and advanced pancreatic cancer patients